SOPHiA Genetics Combines In Vivo And In Vitro Cancer Analyses With Enhanced AI Platform

Clinical genomics company SOPHiA Genetics is integrating new radiomics capabilities to enhance its artificial intelligence (AI) platform SOPHiA, which is already used for analyses of oncology data from liquid biopsy tests. The news marks an increasing trend toward integrating in vivo and in vitro data onto a single diagnostic platform.

Scientists and DDM
• Source: SOPHiA Genetics

Swiss data analytics company SOPHiA Genetics SAis integrating a new radiomics technology to enhance its artificial intelligence (AI) platform, used already for analyzing genomic data from liquid biopsy tests in oncology. The radiomics capabilities were developed through a 10-year research project into mechanistic and mathematical modelling led by mathematics professor Thierry Colin at the INP research center in Bordeaux, France.

"The idea is to use radiology images with machine-learning techniques to predict the evolution of cancer tumors," Tarik Dlala, SOPHiA Genetics' VP of marketing told Medtech Insight

More from Oncology

More from Device Area